Biotechnology The US Food and Drug Administration (FDA) has approved Lazcluze (lazertinib) in combination with Rybrevant (amivantamab-vmjw), from Janssen Biotech, for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). 20 August 2024